Your browser doesn't support javascript.
loading
A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection.
Liu, Qianyun; Jin, Meihua; Mei, Fanghua; Fan, Hui; Gu, Mengxue; Zhang, Yuzhen; Qian, Shengnan; Tan, Xue; Ji, Lei; Zhang, Zhen; Chen, Guozhong; Yan, Huan; Chen, Yu; Lan, Ke; Geng, Qing; Cai, Kun; Zhou, Li.
Afiliación
  • Liu Q; State Key Laboratory of Virology, Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
  • Jin M; State Key Laboratory of Virology, College of Life Sciences, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
  • Mei F; State Key Laboratory of Virology, Modern Virology Research Center and RNA Institute, College of Life Sciences and Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, China.
  • Fan H; Huzhou Center for Disease Control and Prevention, Huzhou, China.
  • Gu M; Hubei Center for Disease Control and Prevention, Wuhan, China.
  • Zhang Y; Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
  • Qian S; State Key Laboratory of Virology, College of Life Sciences, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
  • Tan X; State Key Laboratory of Virology, College of Life Sciences, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
  • Ji L; State Key Laboratory of Virology, College of Life Sciences, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
  • Zhang Z; State Key Laboratory of Virology, College of Life Sciences, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
  • Chen G; Huzhou Center for Disease Control and Prevention, Huzhou, China.
  • Yan H; State Key Laboratory of Virology, Modern Virology Research Center and RNA Institute, College of Life Sciences and Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, China.
  • Chen Y; Animal Biosafety Level (ABSL)-III Laboratory/Institute for Vaccine Research, Wuhan University, Wuhan, China.
  • Lan K; Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
  • Geng Q; State Key Laboratory of Virology, College of Life Sciences, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
  • Cai K; State Key Laboratory of Virology, Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
  • Zhou L; State Key Laboratory of Virology, Modern Virology Research Center and RNA Institute, College of Life Sciences and Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, China.
Front Cell Infect Microbiol ; 14: 1381877, 2024.
Article en En | MEDLINE | ID: mdl-38572316
ABSTRACT
Most of vaccinees and COVID-19 convalescents can build effective anti-SARS-CoV-2 humoral immunity, which helps preventing infection and alleviating symptoms. However, breakthrough viral infections caused by emerging SARS-CoV-2 variants, especially Omicron subvariants, still pose a serious threat to global health. By monitoring the viral infections and the sera neutralization ability of a long-tracked cohort, we found out that the immune evasion of emerging Omicron subvariants and the decreasing neutralization led to the mini-wave of SARS-CoV-2 breakthrough infections. Meanwhile, no significant difference had been found in the infectivity of tested SARS-CoV-2 variants, even though the affinity between human angiotensin-converting enzyme 2 (hACE2) and receptor-binding domain (RBDs) of tested variants showed an increasing trend. Notably, the immune imprinting of inactivated COVID-19 vaccine can be relieved by infections of BA.5.2 and XBB.1.5 variants sequentially. Our data reveal the rising reinfection risk of immune evasion variants like Omicron JN.1 in China, suggesting the importance of booster with updated vaccines.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Humans Idioma: En Revista: Front Cell Infect Microbiol Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Humans Idioma: En Revista: Front Cell Infect Microbiol Año: 2024 Tipo del documento: Article País de afiliación: China